Dr Reddy's Laboratories unveils Raloxifene HCl Tablets, USP in the US market
Dr Reddy's Laboratories unveils Raloxifene HCl Tablets, USP in the US market
About this item
Full title
Dr Reddy's Laboratories unveils Raloxifene HCl Tablets, USP in the US market
Publisher
London: Normans Media Ltd
Journal title
M2 Pharma, 2016
Language
English
Formats
Publication information
Publisher
London: Normans Media Ltd
Subjects
More information
Scope and Contents
Contents
The company said the US Food & Drug Administration (USFDA) approved Raloxifene hydrochloride tablets in 60 mg, is the therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets.
Alternative Titles
Full title
Dr Reddy's Laboratories unveils Raloxifene HCl Tablets, USP in the US market
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_1838672437
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_1838672437
How to access this item
Log in as a Library member
